Ardsley Advisory Partners LP Adma Biologics, Inc. Transaction History

Ardsley Advisory Partners LP

$610 Million
Q2 2025

A detailed history of Ardsley Advisory Partners LP transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Ardsley Advisory Partners LP holds 400,000 shares of ADMA stock, worth $5.84 Million. This represents 1.19% of its overall portfolio holdings.

Number of Shares

400,000

Previous 300,000 33.33%

Holding current value

$5.84 Million

Previous $5.95 Million 22.38%

% of portfolio

1.19%

Previous 1.34%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$17.6 - $24.51 $1.76 Million - $2.45 Million	100,000 Added 33.33%	400,000 $7.28 Million
Q1 2025 May 15, 2025	BUY	$15.44 - $20.61 $4.63 Million - $6.18 Million	300,000 New	300,000 $5.95 Million
Q4 2020 Feb 16, 2021	SELL	$1.8 - $2.56 $169,380 - $240,896	-94,100 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$2.04 - $3.74 $6,120 - $11,220	-3,000 Reduced 3.09%	94,100 $225,000
Q2 2020 Aug 14, 2020	BUY	$2.42 - $3.29 $54,450 - $74,025	22,500 Added 30.16%	97,100 $285,000
Q4 2019 Feb 14, 2020	SELL	$3.89 - $5.15 $124,091 - $164,285	-31,900 Reduced 29.95%	74,600 $298,000
Q3 2019 Nov 14, 2019	BUY	$3.19 - $5.39 $12,415 - $20,977	3,892 Added 3.79%	106,500 $474,000
Q2 2019 Aug 13, 2019	BUY	$3.52 - $5.24 $145,404 - $216,453	41,308 Added 67.39%	102,608 $397,000
Q1 2019 May 15, 2019	BUY	$2.61 - $4.35 $29,493 - $49,154	11,300 Added 22.6%	61,300 $233,000
Q4 2018 Feb 14, 2019	SELL	$2.17 - $6.12 $108,500 - $306,000	-50,000 Reduced 50.0%	50,000 $120,000
Q3 2018 Nov 14, 2018	BUY	$4.39 - $6.85 $87,800 - $137,000	20,000 Added 25.0%	100,000 $621,000
Q2 2018 Aug 14, 2018	BUY	$4.39 - $5.44 $351,200 - $435,200	80,000 New	80,000 $361,000

Others Institutions Holding ADMA

# of Institutions

403

Shares Held

197M

Call Options Held

2.08M

Put Options Held

1.56M

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $2.86B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ardsley Advisory Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Ardsley Advisory Partners LP with notifications on news.

Account

Ardsley Advisory Partners LP Adma Biologics, Inc. Transaction History